- Home
- PRTC vs ZBIO Comparison
PRTC vs ZBIO Comparison
Compare PRTC & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRTC
- ZBIO
- Stock Information
- Founded
- PRTC 2015
- ZBIO 2019
- Country
- PRTC United States
- ZBIO United States
- Employees
- PRTC N/A
- ZBIO N/A
- Industry
- PRTC Biotechnology: Pharmaceutical Preparations
- ZBIO
- Sector
- PRTC Health Care
- ZBIO
- Exchange
- PRTC Nasdaq
- ZBIO NYSE
- Market Cap
- PRTC 414.3M
- ZBIO 389.2M
- IPO Year
- PRTC N/A
- ZBIO 2024
- Fundamental
- Price
- PRTC $18.50
- ZBIO $9.52
- Analyst Decision
- PRTC Buy
- ZBIO Strong Buy
- Analyst Count
- PRTC 1
- ZBIO 7
- Target Price
- PRTC $45.00
- ZBIO $32.29
- AVG Volume (30 Days)
- PRTC 3.2K
- ZBIO 130.3K
- Earning Date
- PRTC 04-30-2025
- ZBIO 05-15-2025
- Dividend Yield
- PRTC N/A
- ZBIO N/A
- EPS Growth
- PRTC N/A
- ZBIO N/A
- EPS
- PRTC 0.21
- ZBIO N/A
- Revenue
- PRTC $4,828,000.00
- ZBIO $15,000,000.00
- Revenue This Year
- PRTC $35.98
- ZBIO N/A
- Revenue Next Year
- PRTC $115.38
- ZBIO N/A
- P/E Ratio
- PRTC $8.24
- ZBIO N/A
- Revenue Growth
- PRTC 44.98
- ZBIO N/A
- 52 Week Low
- PRTC $13.30
- ZBIO $5.83
- 52 Week High
- PRTC $32.98
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- PRTC 58.17
- ZBIO N/A
- Support Level
- PRTC $17.80
- ZBIO N/A
- Resistance Level
- PRTC $19.17
- ZBIO N/A
- Average True Range (ATR)
- PRTC 0.48
- ZBIO 0.00
- MACD
- PRTC 0.13
- ZBIO 0.00
- Stochastic Oscillator
- PRTC 74.72
- ZBIO 0.00
About PRTC PureTech Health plc
PureTech Health PLC is a biopharma company developing medicines to modulate the adaptive human system. It is a cross-disciplinary healthcare company developing products that could improve the lives of patients. The company is focused on developing and commercializing highly differentiated medicines for devastating diseases, including inflammatory, fibrotic, and immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological & neuropsychological disorders, among others. It operates in the following segments: Wholly-Owned Programs, Controlled Founded Entities, and Parent Companies & Others. The company has a robust pipeline of advanced programs that are post-human proof of concept and focused on some of society's healthcare needs.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.